Investing.com -- Shares of Alx Oncology (NASDAQ:ALXO) fell in pre-market trading Thursday after Jefferies downgraded the stock to "hold" rating from a "buy," citing concerns over the company's clinical trial results and the higher burden of proof for its flagship drug, evorpacept.
Jefferies analysts noted that while ALX Oncology initially generated investor excitement with its Phase II interim results in gastric cancer, the complete dataset revealed weaker outcomes.
The study's objective response rate and progression-free survival appeared less compelling upon further analysis.
Analysts attributed the diminished efficacy in the later phases of the trial to inconsistencies, which raised doubts about the drug's performance in broader applications.
The downgrade reflects broader uncertainties tied to the company's pipeline. Jefferies highlighted challenges in the ongoing trials for head and neck cancer, with early data showing only modest differentiation from existing treatments like Keytruda.
Additionally, the experimental combinations with antibody-drug conjugates such as Padcev and Enhertu face low expectations due to limited and non-randomized data.
The analysts underscored financial constraints as a critical factor, with ALX Oncology's cash reserves projected to last only until the first quarter of 2026.
These limitations may hinder the company’s ability to advance its clinical programs effectively, increasing risks for investors.
With ALX Oncology's stock price recently trading at $1.79 and Jefferies reducing its price target to $2, down from $12, the downgrade signals tempered expectations for the company's near-term prospects.
While there remains potential for improved data readouts in 2025, Jefferies said that the burden lies on the company to demonstrate clear and consistent value for its therapies.
Related Articles
Alx Oncology shares down in pre-market as Jefferies downgrades stock to 'hold'
Brazil's central bank intervenes to bolster real amid financial crisis
Dollar Tree names Michael Creedon as permanent CEO to steer turnaround
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。